ConductScience.org, home

Paper40904706

Pleural Mesothelioma: Pathogenesis, Diagnosis, Treatment, Prognosis, and Survival.

Zhang L and 1 other. MedComm (2020), 2025. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Pleural Mesothelioma: Pathogenesis, Diagnosis, Treatment, Prognosis, and Survival. Papers, record 40904706. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40904706

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pleural Mesothelioma: Pathogenesis, Diagnosis, Treatment, Prognosis, and Survival.
PubMed
Journal
MedComm (2020)
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2025-09-15
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhang LLibo
2Huang MMeijuan

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References250

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129587439NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma.Int J Mol Sci2018https://conductscience.org/library/papers/29587439PubMed
229937226LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade.Cell2018https://conductscience.org/library/papers/29937226PubMed
336057027Meta-analysis of survival after extrapleural pneumonectomy (EPP) versus pleurectomy/decortication (P/D) for malignant pleural mesothelioma in the context of macroscopic complete resection (MCR).Updates Surg2022https://conductscience.org/library/papers/36057027PubMed
434069348Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials.Vaccines (Basel)2021https://conductscience.org/library/papers/34069348PubMed
538030172Long Non-coding RNA LINC00152 Requires EZH2 to Promote Mesothelioma Cell Proliferation, Migration, and Invasion.Anticancer Res2023https://conductscience.org/library/papers/38030172PubMed
622127019Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.Mol Ther2012https://conductscience.org/library/papers/22127019PubMed
739159705Unleashing precision: A review of targeted approaches in pleural mesothelioma.Crit Rev Oncol Hematol2024https://conductscience.org/library/papers/39159705PubMed
834363903The transformation of cancer-associated fibroblasts: Current perspectives on the role of TGF-β in CAF mediated tumor progression and therapeutic resistance.Cancer Lett2021https://conductscience.org/library/papers/34363903PubMed
926078352Reactive oxygen species a double-edged sword for mesothelioma.Oncotarget2015https://conductscience.org/library/papers/26078352PubMed
1032226547The biological implications of Yin Yang 1 in the hallmarks of cancer.Theranostics2020https://conductscience.org/library/papers/32226547PubMed
1124094913Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.J Thorac Cardiovasc Surg2014https://conductscience.org/library/papers/24094913PubMed
1233485464First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.Lancet2021https://conductscience.org/library/papers/33485464PubMed
1331367541
A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial.
Transl Lung Cancer Res2019https://conductscience.org/library/papers/31367541PubMed
1428599887Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905).J Thorac Oncol2017https://conductscience.org/library/papers/28599887PubMed
1537748190A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.Mol Cancer Ther2024https://conductscience.org/library/papers/37748190PubMed
1627418105Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages.J Thorac Oncol2016https://conductscience.org/library/papers/27418105PubMed
1730338612Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes.Genes Chromosomes Cancer2018https://conductscience.org/library/papers/30338612PubMed
1840582407Clinical and Pathologic Phenotyping of Mesotheliomas Developing in Carriers of Germline BAP1 Mutations.J Thorac Oncol2025https://conductscience.org/library/papers/40582407PubMed
1918543326Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.Cancer2008https://conductscience.org/library/papers/18543326PubMed
2039495618Real-world outcomes for patients with pleural mesothelioma: A multisite retrospective cohort study.Asia Pac J Clin Oncol2024https://conductscience.org/library/papers/39495618PubMed

See all 250 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42942183Diaphragmatic Reconstruction with StratticeTM Biologic Mesh After Thoracic Oncologic Resection: A 10-Year Single-Center Retrospective Cohort Study.Life (Basel)2026https://conductscience.org/library/papers/42942183PubMed
41982680MET amplification in diffuse pleural mesothelioma and response to savolitinib: a case report.Transl Lung Cancer Res2026https://conductscience.org/library/papers/41982680PubMed
41510382Real-world outcomes of first-line immunotherapy and subsequent systemic therapies in pleural mesothelioma: a multicenter study in China.Transl Lung Cancer Res2025https://conductscience.org/library/papers/41510382PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40904706

GET https://conductscience.org/api/papers/v1/40904706/references?page=2